 NEW YORK, Feb. 10, 2022 GLOBE NEWSWIRE -- IN8bio, Inc. Nasdaq: INAB, a clinical-stage gamma-delta T cell therapies biopharmaceutical company today announced that Company executives will be presenting at the following events: 